These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Pregnancy associated with lupus anticoagulant and heparin induced thrombocytopenia: management with a low molecular weight heparinoid. van Besien K; Hoffman R; Golichowski A Thromb Res; 1991 Apr; 62(1-2):23-9. PubMed ID: 1712988 [TBL] [Abstract][Full Text] [Related]
24. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Magnani HN Thromb Haemost; 1993 Oct; 70(4):554-61. PubMed ID: 7509508 [TBL] [Abstract][Full Text] [Related]
25. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise. de Boer A; Kluft C; Dooijewaard G; Kasper FJ; Kroon JM; Breimer DD; Stiekema JC; Cohen AF Thromb Haemost; 1992 Nov; 68(5):550-5. PubMed ID: 1280862 [TBL] [Abstract][Full Text] [Related]
26. Time courses of the antithrombotic effects, bleeding enhancing effects and interactions with factors Xa and thrombin after administration of low molecular weight heparinoid Org 10172 or heparin to rats. Hobbelen PM; Vogel GM; Meuleman DG Thromb Res; 1987 Dec; 48(5):549-58. PubMed ID: 3481660 [TBL] [Abstract][Full Text] [Related]
27. Gastrointestinal blood loss in haemodialysis patients during use of a low-molecular-weight heparinoid anticoagulant. Frei U; Wilks MF; Boehmer S; Crisp-Lindgren N; Schwarzrock R; Stiekema JC; Koch KM Nephrol Dial Transplant; 1988; 3(4):435-9. PubMed ID: 2459635 [TBL] [Abstract][Full Text] [Related]
28. Heparin-associated thrombocytopenia: successful therapy with the heparinoid Org 10172 in a patient showing cross-reaction to LMW heparins. Greinacher A; Drost W; Michels I; Leitl J; Gottsmann M; Kohl HJ; Glaser M; Mueller-Eckhardt C Ann Hematol; 1992 Jan; 64(1):40-2. PubMed ID: 1310879 [TBL] [Abstract][Full Text] [Related]
29. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. A randomized, double-blind study. Turpie AG; Gent M; Côte R; Levine MN; Ginsberg JS; Powers PJ; Leclerc J; Geerts W; Jay R; Neemeh J Ann Intern Med; 1992 Sep; 117(5):353-7. PubMed ID: 1503326 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Danhof M; de Boer A; Magnani HN; Stiekema JC Haemostasis; 1992; 22(2):73-84. PubMed ID: 1379967 [TBL] [Abstract][Full Text] [Related]
31. Heparin-induced thrombocytopenia and arterial thrombosis: alternative therapies. Cola C; Ansell J Am Heart J; 1990 Feb; 119(2 Pt 1):368-74. PubMed ID: 1689094 [TBL] [Abstract][Full Text] [Related]
32. Can low molecular weight heparins and heparinoids be safely given to patients with heparin-induced thrombocytopenia syndrome? Kikta MJ; Keller MP; Humphrey PW; Silver D Surgery; 1993 Oct; 114(4):705-10. PubMed ID: 7692613 [TBL] [Abstract][Full Text] [Related]
33. Orgaran in the prevention of deep vein thrombosis in stroke patients. Turpie AG Haemostasis; 1992; 22(2):92-8. PubMed ID: 1379969 [TBL] [Abstract][Full Text] [Related]
34. ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Bradbrook ID; Magnani HN; Moelker HC; Morrison PJ; Robinson J; Rogers HJ; Spector RG; Van Dinther T; Wijnand H Br J Clin Pharmacol; 1987 Jun; 23(6):667-75. PubMed ID: 3606928 [TBL] [Abstract][Full Text] [Related]
35. Large-dose infusions of heparinoid ORG 10172 in ischemic stroke. Massey EW; Biller J; Davis JN; Adams HP; Marler JR; Goldstein LB; Alberts M; Bruno A Stroke; 1990 Sep; 21(9):1289-92. PubMed ID: 2396265 [TBL] [Abstract][Full Text] [Related]
36. Successful use of the APTT in monitoring of the anti-factor Xa activity of the heparinoid organon 10172 in a case of HITS requiring open heart surgery. Marshall LR; Cannell PK; Herrmann RP Thromb Haemost; 1992 May; 67(5):587. PubMed ID: 1519220 [No Abstract] [Full Text] [Related]
37. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial. Gerhart TN; Yett HS; Robertson LK; Lee MA; Smith M; Salzman EW J Bone Joint Surg Am; 1991 Apr; 73(4):494-502. PubMed ID: 1707413 [TBL] [Abstract][Full Text] [Related]
38. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators' Group. Gallus A; Cade J; Ockelford P; Hepburn S; Maas M; Magnani H; Bucknall T; Stevens J; Porteous F Thromb Haemost; 1993 Oct; 70(4):562-7. PubMed ID: 7509509 [TBL] [Abstract][Full Text] [Related]
39. Randomized double-blind, placebo controlled safety study of a low molecular weight heparinoid in patients undergoing transurethral resection of the prostate. ten Cate H; Henny CP; ten Cate JW; Büller HR; Dabhoiwala NF Thromb Haemost; 1987 Feb; 57(1):92-6. PubMed ID: 2438799 [TBL] [Abstract][Full Text] [Related]
40. A dose escalation study of ORG 10172 (low molecular weight heparinoid) in stroke. Biller J; Massey EW; Marler JR; Adams HP; Davis JN; Bruno A; Henriksen RA; Linhardt RJ; Goldstein LB; Alberts M Neurology; 1989 Feb; 39(2 Pt 1):262-5. PubMed ID: 2464774 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]